Trial reportCancer prevention research (Philadelphia, Pa.)2019
Effect of Bazedoxifene and Conjugated Estrogen (Duavee) on Breast Cancer Risk Biomarkers in High-Risk Women: A Pilot Study.
Trial report in Cancer prevention research (Philadelphia, Pa.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pilot Study of the Effect of Duavee® on Benign Breast Tissue Proliferation in Peri or Post-menopausal Women at Moderate Risk for Development of Breast Cancer
Pilot Study of Effects of Duavee® on Imaging and Blood Biomarkers In Women With Menopausal Symptoms at Increased Risk for Breast Cancer
Randomized IIB Study of the Effect of Bazedoxifene Plus Conjugated Estrogens on Breast Imaging and Tissue Biomarkers in Peri or Post-Menopausal Women at Increased Risk for Development of Breast Cancer
Pilot Study of Effects of Bazedoxifene Plus Conjugated Estrogen on Imaging and Blood Biomarkers In Women With Menopausal Symptoms at Increased Risk for Breast Cancer
Who cites it
20 citing papers in PubMed, 40 citations in OpenAlex.
- Trial
- 1Molecules (Basel, Switzerland) · 2025Article
- The 2025 Menopausal Hormone Therapy Guidelines - Korean Society of Menopause.Journal of menopausal medicine · 2025Review
- Metabolic and transcriptional effects of bazedoxifene/conjugated estrogens in a model of obesity-associated breast cancer risk.JCI insight · 2025Article
- Mammographic Density in Relation to Breast Cancer Risk Factors among Chinese Women.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Domino Synthesis of 1,2,5-Trisubstituted 1Molecules (Basel, Switzerland) · 2025Article
- A roadmap to reduce the incidence and mortality of breast cancer by rethinking our approach to women's health.Breast cancer research and treatment · 2025Review
- Article
- MRI-based Deep Learning Models for Preoperative Breast Volume and Density Assessment Assisting Breast Reconstruction.Aesthetic plastic surgery · 2024Article
- Overcoming challenges in conducting early phase breast cancer prevention trials: Bazedoxifene and conjugated estrogens vs waitlist control.Contemporary clinical trials · 2024Article
- Bazedoxifene as a Potential Cancer Therapeutic Agent Targeting IL-6/GP130 Signaling.Current oncology (Toronto, Ont.) · 2024Review
- Diabetes mellitus in breast cancer survivors: metabolic effects of endocrine therapy.Nature reviews. Endocrinology · 2024Review
- Endometrial Cancer Risk Among GermlineJCO precision oncology · 2023Review
- Hormone therapy for sexual function in perimenopausal and postmenopausal women.The Cochrane database of systematic reviews · 2023Review
- Vanillin-Based Indolin-2-one Derivative Bearing a Pyridyl Moiety as a Promising Anti-Breast Cancer Agent via Anti-Estrogenic Activity.ACS omega · 2023Article
- Targeting nuclear hormone receptors for the prevention of breast cancer.Frontiers in medicine · 2023Review
- Quantitative Breast Density in Contrast-Enhanced Mammography.Journal of clinical medicine · 2021Article
- Breast Cancer and Microcalcifications: An Osteoimmunological Disorder?International journal of molecular sciences · 2020Review
- Selective estrogen receptor modulators in the prevention of breast cancer in premenopausal women: a review.Translational cancer research · 2020Review
- Computer-Aided Ligand Discovery for Estrogen Receptor Alpha.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
Abstract
Interventions that relieve vasomotor symptoms while reducing risk for breast cancer would likely improve uptake of chemoprevention for perimenopausal and postmenopausal women. We conducted a pilot study with 6 months of the tissue selective estrogen complex bazedoxifene (20 mg) and conjugated estrogen (0.45 mg; Duavee) to assess feasibility and effects on risk biomarkers for postmenopausal breast cancer. Risk biomarkers included fully automated mammographic volumetric density (Volpara), benign breast tissue Ki-67 (MIB-1 immunochemistry), and serum levels of progesterone, IGF-1, and IGFBP3, bioavailable estradiol and testosterone. Twenty-eight perimenopausal and postmenopausal women at increased risk for breast cancer were enrolled: 13 in cohort A with baseline Ki-67 < 1% and 15 in cohort B with baseline Ki-67 of 1% to 4%. All completed the study with > 85% drug adherence. Significant changes in biomarkers, uncorrected for multiple comparisons, were a decrease in mammographic fibroglandular volume (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.